The modern journey began when Swiss chemist Albert Hofmann synthesised LSD in 1938. In the 1970s and 80s, researchers found that these drugs attach to a specific brain receptor (called 5-HT2A) that ...

Tripping on psychedelics is hard to describe to someone who’s never been through the experience. Every psychedelic trip is ...

With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s disease therapeutic in the US by 2027.

Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data ...

Baidu’s Apollo Go, WeRide and Pony.ai have been granted permits by Dubai’s Roads and Transport Authority (RTA) to conduct autonomous driving trials on the emirate’s roads, enabling the companies to ...

A psychoactive ingredient found in ayahuasca, a brew used in shamanistic rituals in South America, has shown promise as a treatment for depression in a phase 2a trial. In the study, 34 people living ...

Study finds participants saw reduction in depressive symptoms as researchers welcome ‘promising’ results A phase II clinical trial has found dimethyltryptamine (DMT), one of the psychoactive ...

A recent study in Translational Psychiatry shows that one dose of DMT reversed loss of pleasure and cognitive deficits in stressed mice. The psychedelic promoted new brain cell growth, highlighting ...

"The general level of hypervigilance is rising across society," says curator Mark Atkin. "Embedded within each experience is ...